

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,926	01/16/2002	Jeffrey R. Sampson	2003309-0027 (Agilent 10	1042
	7590 06/12/200 CHNOLOGIES, INC.	EXAMINER		
Legal Departme	ent, DL429		MUMMERT, STEPHANIE KANE	
Intellectual Property Administration P.O. Box 7599 Loveland, CO 80537-0599			ART UNIT	PAPER NUMBER
			1637	
			MAIL DATE	DELIVERY MODE
			06/12/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/052,926	SAMPSON, JEFFREY R.	
Examiner	Art Unit	
STEPHANIE K. MUMMERT	1637	

Th	ne MAILING DATE of this communication appears on	the cover sheet with the correspondence address
THE REPLY F	FILED <u>09 May 2008</u> FAILS TO PLACE THIS A <mark>PPLI</mark> CATI	ON IN CONDITION FOR ALLOWANCE.
applicati applicati	ion, applicant must timely file one of the following replies: ion in condition for allowance; (2) a Notice of Appeal (with inued Examination (RCE) in compliance with 37 CFR 1.1	me day as filing a Notice of Appeal. To avoid abandonment of this (1) an amendment, affidavit, or other evidence, which places the h appeal fee) in compliance with 37 CFR 41.31; or (3) a Request 114. The reply must be filed within one of the following time
<u>—</u>	period for reply expiresmonths from the mailing date of	f the final rejection.
b) 🖾 The no e Exar	period for reply expires on: (1) the mailing date of this Advisory vent, however, will the statutory period for reply expire later that miner Note: If box 1 is checked, check either box (a) or (b). ONL	Action, or (2) the date set forth in the final rejection, whichever is later. In
Extensions of tin have been filed under 37 CFR 1 set forth in (b) a	is the date for purposes of determining the period of extension a 1.17(a) is calculated from: (1) the expiration date of the shortene above, if checked. Any reply received by the Office later than the parened patent term adjustment. See 37 CFR 1.704(b).	h the petition under 37 CFR 1.136(a) and the appropriate extension fee and the corresponding amount of the fee. The appropriate extension fee ad statutory period for reply originally set in the final Office action; or (2) as ree months after the mailing date of the final rejection, even if timely filed,
filing the	e Notice of Appeal (37 CFR 41.37(a)), or any extension the fappeal has been filed, any reply must be filed within the	with 37 CFR 41.37 must be filed within two months of the date of nereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a e time period set forth in 37 CFR 41.37(a).
3. ☐ The pro (a)☐ Th	oposed amendment(s) filed after a final rejection, but prioney raise new issues that would require further considerately raise the issue of new matter (see NOTE below);	• · · —
(c) Tr	hey are not deemed to place the application in better forn ppeal; and/or	n for appeal by materially reducing or simplifying the issues for
· / — N	hey present additional claims without canceling a corresp NOTE: (See 37 CFR 1.116 and 41.33(a)).	•
		e attached Notice of Non-Compliant Amendment (PTOL-324).
	ant's reply has overcome the following rejection(s):	
non-allo	wable claim(s).	e if submitted in a separate, timely filed amendment canceling the
how the The stat Claim(s) Claim(s) Claim(s)	coses of appeal, the proposed amendment(s): a) will new or amended claims would be rejected is provided by the state of the claim(s) is (or will be) as follows: allowed: b) objected to: rejected: 1-35,67-101 and 144-149. withdrawn from consideration:	not be entered, or b) 🔯 will be entered and an explanation of elow or appended.
	PROTHER EVIDENCE	
8. The affice because	davit or other evidence filed after a final action, but before	e or on the date of filing a Notice of Appeal will <u>not</u> be entered ient reasons why the affidavit or other evidence is necessary and
entered		te of Appeal, but prior to the date of filing a brief, will <u>not</u> be the <u>all</u> rejections under appeal and/or appellant fails to provide a vas not earlier presented. See 37 CFR 41.33(d)(1).
	fidavit or other evidence is entered. An explanation of the OR RECONSIDERATION/OTHER	e status of the claims after entry is below or attached.
11. 🛛 The red		NOT place the application in condition for allowance because:
12.	ne attached Information <i>Discl</i> os <i>ure Statement</i> (s). (PTO/S	SB/08) Paper No(s)
/GARY BEI	NZION/	/Stephanie K. Mummert/
	Patent Examiner, Art Unit 1637	Patent Examiner, Art Unit 1637

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's arguments have been considered, but they are not persuasive. First, it is noted that Applicant is arguing a scope of the invention that is not commensurate with the claims as currently stated. Applicant is arguing the inclusion of two different complementary base pair analogs within unstructured nucleic acids. That argument only addresses claims 5 and 71. The independent claim which includes the two different complementary base pair analogs does not explicitly require that the nucleic acid has to be in the form of UNA (unstructured nucleic acids) as argued by Applicant.

Regarding Kutyavin, Applicant argues that "Kutyavin is merely directed to inter-molecular interactions and discloses oligonucleotides in which 'complementary positions in both SBC ODNs are modified into a matched pair of SBC ODNs of the present invention so that the pair of the matched set does not form a stable hybrid" (p. 12 of remarks). While Applicant's arguments are noted, that Kutyavin does not explicitly teach that these nucleotides would also result in a reduction in intramolecular secondary structure, it is noted in response that these modified nucleotides would inherently reduce secondary structure in an intra-molecular setting, in addition to the findings regarding inter-molecular interactions. If the hybrids formed between these nucleotides are reduced inter-molecularly, hybrids formed intramolecularly would also be reduced, resulting in reduced secondary structure. It is also noted that Kutyavin teaches the same modified analogs as claimed in dependent claim 33-34 and so would be expected to function in the same manner as claimed.

Furthermore, Applicant is arguing against Kutyavin alone, when Kutyavin is relied upon primarily for the teaching of the inclusion of 2-aminoadenosine and 2-thiothymidine nucleotides to reduce secondary structure and this teaching is provided in view of the teachings of Church and Morgan. Morgan also teaches the inclusion of modified or analog nucleotides which reduce secondary structure in the nucleic acid molecule. Morgan specifically teaches the inclusion of inosine to reduce secondary structure. Kutyavin does not stand alone and renders the claims obvious only in view of the combined teachings of Church and Morgan, to achieve nucleic acids in which secondary structure is reduced through the inclusion of analog nucleotides.

Regarding Applicant's arguments "the use of UNA nucleotides to decrease intra-molecular interactions might in hindsight appear to be a straightforward extension of prior art methods" (p. 11 of remarks) are also noted. However, it is noted again that the base rejection of the independent claim does not require unstructure nucleic acids where the secondary structure is reduced. The claim only requires that the secondary structure of the nucleic acid is reduced through the inclusion of modified or analog nucleotides. The rejections are maintained because the prior art teaches the inclusion of modified nucleotides for the reduction in secondary structure as taught by Morgan and Kutyavin. The prior art also teaches the method of nanopore sequencing as taught by Church. These references in combination render the claimed invention obvious.

It is also noted, in response to Applicant's arguments regarding KSR, that KSR also advises that the combination of known prior art elements to achieve a predictable result is another rationale to support a finding of obviousness. While Applicant's arguments regarding a lack of motivation are noted, it is noted in response that one of ordinary skill would have known to look to the known prior art elements of analog nucleotides like inosine, 2-thiothymidine, 2-aminoadenosine, which are also known to reduce binding and to reduce secondary structure. Therefore, even in the absence of an explicit motivation, one of ordinary skill would have recognized that including modified nucleotides in a nucleic acid molecule would achieve a predictable result of reduction in secondary structure. Therefore, the rejection is maintained.

Applicant traverses the rejection of dependent claims in view of Lizardi and in view of Thorp. The arguments against these dependent claims are based on the arguments addressed above. These rejections are maintained for the reasons previously stated above.